{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:20:26Z","timestamp":1790659226767,"version":"4.1.0"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this review is to evaluate the efficacy and safety of plozasiran, a novel agent recently approved by the US Food and Drug Administration for familial chylomicronemia syndrome (FCS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>\n                      A comprehensive literature search was conducted in PubMed and the National Institutes of Health Clinical Trials Registry (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      ) from April 2014 to April 2026 using the keyword \u201cplozasiran.\u201d Trials that were phase 1 trials, review papers, pooled analyses of trials, or ongoing studies without complete results were excluded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Phase 2 and 3 trials assessing plozasiran\u2019s safety and efficacy were included. Initially, 57 articles were yielded, and 3 studies were included after application of inclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>The findings from this review indicate that plozasiran is overall a safe and effective medication to significantly lower triglycerides and acute pancreatitis in patients with FCS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:<\/jats:title>\n                    <jats:p>Plozasiran is a novel agent that targets a similar pathway as olezarsen but requires less frequent administration (4 times a year for plozasiran vs 12 times a year for olezarsen). While this may help with patient adherence compared to olezarsen, plozasiran\u2019s higher annual cost (approximately $72\u2009000\/year) compared to olezarsen ($40\u2009000\/year) may limit use for FCS management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Plozasiran offers an alternative pharmacological agent to olezarsen for management of FCS in the United States. Currently, there are limited data evaluating the long-term outcomes of plozasiran use in patients with FCS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261452675","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T11:33:08Z","timestamp":1780745588000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["ApoC[III] You Later: A Review of Plozasiran for the Management of Familial Chylomicronemia Syndrome"],"prefix":"10.1177","author":[{"given":"Ellen B.","family":"Yin","sequence":"first","affiliation":[{"name":"University of Houston College of Pharmacy, TX, USA"},{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4832-8200","authenticated-orcid":false,"given":"Matthew A.","family":"Wanat","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5655-5318","authenticated-orcid":false,"given":"Elisabeth M.","family":"Wang","sequence":"additional","affiliation":[{"name":"University of Houston College of Pharmacy, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-025-00774-5"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.119114"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.814"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.09.008"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.03.013"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae613"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-025-01345-4"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715944"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00046-2"},{"key":"e_1_3_2_11_2","unstructured":"U.S. Food and Drug Administration. FDA approves drug to reduce triglycerides in adults patients with familial chylomicronemia syndrome. Published December 19 2024. Accessed March 9 2026. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-reduce-triglycerides-adult-patients-familial-chylomicronemia-syndrome"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400201"},{"key":"e_1_3_2_13_2","unstructured":"U.S. Food and Drug Administration. FDA approves drug to reduce triglycerides in adults with familial chylomicronemia syndrome. Published November 18 2025. Accessed March 9 2026. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-reduce-triglycerides-adults-familial-chylomicronemia-syndrome"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-026-02293-2"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.58347\/tml.2026.1752c"},{"key":"e_1_3_2_16_2","unstructured":"Redemplo (Plozasiran) [package insert]. Arrowhead Pharmaceuticals Inc.; 2025. Accessed March 6 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219947s000lbl.pdf"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2026.01.026"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.0959"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00796"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.12.2966"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404143"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409368"},{"key":"e_1_3_2_23_2","unstructured":"Arrowhead Pharmaceuticals. Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia. ClinicalTrials.gov;2025 Accessed April 1 2026. https:\/\/clinicaltrials.gov\/study\/NCT06347133"},{"key":"e_1_3_2_24_2","unstructured":"Arrowhead Pharmaceuticals. Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia. ClinicalTrials.gov;2025. Accessed April 1 2026. https:\/\/clinicaltrials.gov\/study\/NCT06347003"},{"key":"e_1_3_2_25_2","unstructured":"Arrowhead Pharmaceuticals. Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia. ClinicalTrials.gov;2025. Accessed April 1 2026. https:\/\/clinicaltrials.gov\/study\/NCT06347016"},{"key":"e_1_3_2_26_2","unstructured":"Arrowhead Pharmaceuticals. Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study). ClinicalTrials.gov;2026. Accessed April 1 2026. https:\/\/clinicaltrials.gov\/study\/NCT06880770"},{"key":"e_1_3_2_27_2","unstructured":"Arrowhead Pharmaceuticals. A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceri-demia (SHASTA-10 Study). ClinicalTrials.gov; 2026. Accessed April 1 2026. https:\/\/clinicaltrials.gov\/study\/NCT06822790"},{"key":"e_1_3_2_28_2","unstructured":"Visirna Therapeutics HK Limited. A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 \/ VSA001 \/ SAR449124 Injection in Chinese Adults With Familial Chylomicronemia Syndrome. ClinicalTrials.gov; 2026. Accessed April 1 2026. https:\/\/clinicaltrials.gov\/study\/NCT05902598"},{"key":"e_1_3_2_29_2","unstructured":"Rely On Redemplo\u00ae Patient Support. Get Started Today. Accessed March 31 2026. https:\/\/redemplo.com\/access-and-support"},{"key":"e_1_3_2_30_2","unstructured":"Tryngolza [package insert]. Ionis Pharmaceuticals Inc.; 2024. Accessed July 2025. https:\/\/ionis.com\/sites\/default\/files\/2025-03\/TRYNGOLZA-olezarsen-FPI.pdf"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280251332500"},{"key":"e_1_3_2_32_2","unstructured":"Ionis statement about the wholesale acquisition cost of TRYNGOLZA (Olezarsen). Published March 25 2026. Accessed April 8 2026. https:\/\/ir.ionis.com\/static-files\/ebde7dc2-f02f-4285-813c-fb744951c848"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261452675","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261452675","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261452675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:53:16Z","timestamp":1780991596000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261452675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":31,"alternative-id":["10.1177\/10600280261452675"],"URL":"https:\/\/doi.org\/10.1177\/10600280261452675","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"article-number":"10600280261452675"}}